Skip to content
PubMed This is a summary of 35 peer-reviewed journal articles Updated
Neurology

Adult Polyglucosan Body Disease (APBD): A Patient Guide

At a Glance

APBD is a rare genetic disorder that causes abnormal glycogen deposits to build up in the nervous system. Symptoms often include bladder problems, stiff or weak legs, and loss of sensation in the feet, but progression varies. Care prioritizes kidney protection, mobility, and rehabilitation.

Adult Polyglucosan Body Disease (APBD) is an ultra-rare genetic disorder that typically begins to show its first signs when a person is in their 50s or 60s. At its core, the condition is caused by a mutation in the GBE1 gene, which provides instructions for making the glycogen branching enzyme. This enzyme is needed to properly branch glycogen, the stored form of sugar used for energy. Without enough functional enzyme, the glycogen becomes stiff and insoluble, clumping into deposits called polyglucosan bodies. Over several decades, these bodies slowly accumulate within the brain, spinal cord, and peripheral nerves, eventually interfering with the body’s ability to send and receive essential signals [1][2].

Because APBD is so rare and its symptoms develop so gradually, many people endure a long diagnostic odyssey before finding the correct answer. The disease is frequently misdiagnosed as more common conditions such as prostate disease in men, Multiple Sclerosis (MS), or peripheral neuropathy. This happens because APBD often presents with a suggestive pattern of symptoms that overlaps with many other disorders: a neurogenic bladder that doesn’t empty or signal correctly, a progressive stiffness and weakness in the legs known as spastic paraplegia, and a loss of sensation in the feet called peripheral neuropathy [3][4].

While the condition is progressive, its course is variable and depends on a person’s individual biology and physical state at the time of diagnosis. Some individuals may remain relatively stable for years, while others may experience a more noticeable change in their mobility over time. Understanding this variability is vital, as it means that one person’s journey with APBD may look very different from another’s. Research has explored various dietary and metabolic treatments, such as triheptanoin, but these have not yet proven to be effective at stopping the underlying disease process [5][6].

In the absence of a disease-modifying cure, the current mainstay of care is proactive, multidisciplinary symptom management. This approach focuses on protecting vital organ function—specifically the kidneys—and maintaining independence through physical therapy and the use of assistive devices. By assembling a team of specialists who understand the unique intersection of neurology and urology, patients can manage the complexities of the disease effectively. While the diagnosis is life-changing, a focus on coordinated care and long-term planning allows patients and their families to navigate the path forward with clarity and purpose [7][8].

What Should I Do Next?

If you have just been diagnosed with APBD, the next steps can feel overwhelming. Focus on these priorities:

  1. Confirm Your Genetics: Review your genetic report with a genetic counselor or neuromuscular specialist to ensure your diagnosis is fully confirmed.
  2. Protect Your Kidneys: Arrange a comprehensive bladder and kidney assessment with a neuro-urologist.
  3. Prioritize Safety: Obtain a rehabilitation and fall-risk evaluation from a physical therapist.
  4. Find Your Quarterback: Identify one clinician—often a neurologist—who will coordinate care across your different specialists.

Common questions in this guide

Why does adult polyglucosan body disease happen?
APBD is caused by a mutation in the GBE1 gene, which provides instructions for the glycogen branching enzyme. When the enzyme does not work properly, stiff, insoluble glycogen deposits called polyglucosan bodies can build up in the brain, spinal cord, and peripheral nerves.
What symptoms are typical of APBD?
APBD commonly causes a bladder that does not empty or signal normally, stiffness and weakness in the legs, and reduced sensation in the feet. These problems are often described as neurogenic bladder, spastic paraplegia, and peripheral neuropathy, and they usually develop gradually.
How is APBD confirmed after a suspected diagnosis?
Confirmation involves reviewing the genetic report for the GBE1 mutation with a genetic counselor or neuromuscular specialist. A neurologist can also compare the symptom pattern with other conditions that may look similar, such as multiple sclerosis or prostate-related urinary problems.
How can APBD care protect my health and independence?
Care is usually multidisciplinary, with attention to bladder and kidney function, mobility, and safety. A neuro-urologist can assess urinary and kidney risks, while physical therapy, rehabilitation, and assistive devices can support movement and safety; one clinician, often a neurologist, can coordinate the team.
Is there a treatment that stops APBD from progressing?
There is currently no disease-modifying cure proven to stop the underlying APBD process. Dietary or metabolic approaches such as triheptanoin have been studied, but they have not yet shown that they can stop the disease.
Why can APBD be mistaken for other conditions?
APBD develops slowly and can resemble more common problems because bladder dysfunction, stiff or weak legs, and sensory loss overlap with conditions such as multiple sclerosis, peripheral neuropathy, or prostate disease. Genetic confirmation and review by clinicians familiar with neurology and urology can help clarify the diagnosis, although a person could also have another condition at the same time.
What should I ask for soon after an APBD diagnosis?
Early priorities include reviewing the genetic diagnosis, arranging a bladder and kidney assessment, and having a rehabilitation and fall-risk evaluation. Ask which clinician will coordinate follow-up and which baseline measures should be repeated to track changes over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that APBD is ultra-rare, how can we ensure my local care team stays updated on the latest management standards?
  2. 2.How do we distinguish my specific symptoms from more common conditions like prostate enlargement or Multiple Sclerosis, keeping in mind I could have both?
  3. 3.Can you help me identify the 'quarterback' of my care team who will coordinate between neurology and urology?
  4. 4.What are the most important baseline tests I should have now to track my progression over the coming years?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Unifying the Communities of Early-Onset Glycogen Storage Disease Type IV and Adult Polyglucosan Body Disease Through a Genetic Prevalence Study of GBE1-Related Disease.

    Koch RL, Akman HO, Chown E, et al.

    JIMD reports 2026; (67(3)):e70080 doi:10.1002/jmd2.70080.

    PMID: 41948007
  2. 2

    A novel mouse model that recapitulates adult-onset glycogenosis type 4.

    Orhan Akman H, Emmanuele V, Kurt YG, et al.

    Human molecular genetics 2015; (24(23)):6801-10 doi:10.1093/hmg/ddv385.

    PMID: 26385640
  3. 3

    Frequent misdiagnosis of adult polyglucosan body disease.

    Hellmann MA, Kakhlon O, Landau EH, et al.

    Journal of neurology 2015; (262(10)):2346-51 doi:10.1007/s00415-015-7859-4.

    PMID: 26194201
  4. 4

    GBE1-related disorders: Adult polyglucosan body disease and its neuromuscular phenotypes.

    Souza PVS, Badia BML, Farias IB, et al.

    Journal of inherited metabolic disease 2021; (44(3)):534-543 doi:10.1002/jimd.12325.

    PMID: 33141444
  5. 5

    A double-blind, placebo-controlled trial of triheptanoin in adult polyglucosan body disease and open-label, long-term outcome.

    Schiffmann R, Wallace ME, Rinaldi D, et al.

    Journal of inherited metabolic disease 2018; (41(5)):877-883 doi:10.1007/s10545-017-0103-x.

    PMID: 29110179
  6. 6

    Adult polyglucosan body disease - Management and evolution in an intensive rehabilitation program.

    Carneiro I, Rodrigues M, Costa AJ, et al.

    Rehabilitacion 2021; (55(2)):161-163 doi:10.1016/j.rh.2020.06.009.

    PMID: 33139012
  7. 7

    Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource.

    Koch RL, Soler-Alfonso C, Kiely BT, et al.

    Molecular genetics and metabolism 2023; (138(3)):107525 doi:10.1016/j.ymgme.2023.107525.

    PMID: 36796138
  8. 8

    Perspectives on urological care in multiple sclerosis patients.

    Moussa M, Abou Chakra M, Papatsoris AG, et al.

    Intractable & rare diseases research 2021; (10(2)):62-74 doi:10.5582/irdr.2021.01029.

    PMID: 33996350

This APBD guide is for informational purposes only and does not constitute medical advice. Discuss genetic confirmation, bladder and kidney protection, rehabilitation, and care coordination with your neurologist and other specialists.

Get notified when new evidence is published on Adult polyglucosan body disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.